2. Academic Validation
  3. Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

  • J Med Chem. 2022 Jan 13;65(1):409-423. doi: 10.1021/acs.jmedchem.1c01586.
Caroline Wilson 1,  Peter Ray 1,  Fabio Zuccotto 1,  Jorge Hernandez 1,  Anup Aggarwal 2,  Claire Mackenzie 1,  Nicola Caldwell 1,  Malcolm Taylor 1,  Margaret Huggett 1,  Michael Mathieson 1,  Dinakaran Murugesan 1,  Alasdair Smith 1,  Susan Davis 1,  Mattia Cocco 1,  Maloy K Parai 2,  Arjun Acharya 2,  Fabio Tamaki 1,  Paul Scullion 1,  Ola Epemolu 1,  Jennifer Riley 1,  Laste Stojanovski 1,  Eva Maria Lopez-Román 3,  Pedro Alfonso Torres-Gómez 3,  Ana Maria Toledo 3,  Laura Guijarro-Lopez 3,  Isabel Camino 3,  Curtis A Engelhart 4,  Dirk Schnappinger 4,  Lisa M Massoudi 5,  Anne Lenaerts 5,  Gregory T Robertson 5,  Chris Walpole 6,  David Matthews 6,  David Floyd 6,  James C Sacchettini 2,  Kevin D Read 1,  Lourdes Encinas 3,  Robert H Bates 3,  Simon R Green 1,  Paul G Wyatt 1
Affiliations

Affiliations

  • 1 Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
  • 2 Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843, United States.
  • 3 Global Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
  • 4 Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.
  • 5 Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 200 W. Lake Street, Fort Collins, Colorado 80523-1682, United States.
  • 6 Structural Genomics Consortium, Research Institute of the McGill University Health Centre, 1001 Boulevard Décarie, Site Glen Block E, ES1.1614, Montréal, Québec H4A 3J1, Canada.
PMID: 34910486 DOI: 10.1021/acs.jmedchem.1c01586
Abstract

With increasing drug resistance in tuberculosis (TB) patient populations, there is an urgent need for new drugs. Ideally, new agents should work through novel targets so that they are unencumbered by preexisting clinical resistance to current treatments. Benzofuran 1 was identified as a potential lead for TB inhibiting a novel target, the thioesterase domain of Pks13. Although, having promising activity against Mycobacterium tuberculosis, its main liability was inhibition of the hERG cardiac ion channel. This article describes the optimization of the series toward a preclinical candidate. Despite improvements in the hERG liability in vitro, when new compounds were assessed in ex vivo cardiotoxicity models, they still induced cardiac irregularities. Further series development was stopped because of concerns around an insufficient safety window. However, the demonstration of in vivo activity for multiple series members further validates Pks13 as an attractive novel target for antitubercular drugs and supports development of alternative chemotypes.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z